Legend Biotech (LEGN) Income towards Parent Company (2019 - 2025)
Legend Biotech (LEGN) posted Income towards Parent Company of -$8.4 million for Q4 2025, up 78.16% on a QoQ basis from -$38.5 million in Q3 2025, and down 32058.61% year-over-year from N/an in Q4 2024.
Legend Biotech (LEGN) has 7 years of Income towards Parent Company data on file, last reported at -$8.4 million in Q4 2025.
- In Q4 2025, Income towards Parent Company fell 32058.61% year-over-year to -$8.4 million; the TTM figure through Dec 2025 stood at -$272.0 million (up 37.07% YoY), while the FY2025 annual figure was -$268.4 million, down 151516.15% from the prior year.
- Income towards Parent Company rose to -$8.4 million in Q4 2025, from -$38.5 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $26284.0 in Q4 2024 and bottomed at -$199.1 million in Q2 2023.
- A 5-year average of -$91.4 million and a median of -$96.2 million in 2021 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2022 — Income towards Parent Company slumped 35570.18% — and 2024, when it jumped 118.15%.
- Year by year, Income towards Parent Company stood at -$88.3 million in 2021, then plunged by 53.82% to -$135.9 million in 2022, then soared by 99.89% to -$144818.0 in 2023, then surged by 118.15% to $26284.0 in 2024, then tumbled by 32058.61% to -$8.4 million in 2025.
- The last three Income towards Parent Company figures came in at -$8.4 million (Q4 2025), -$38.5 million (Q3 2025), and -$124.2 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -8.50 Mn |
| Sep 30, 2025 | -38.46 Mn |
| Jun 30, 2025 | -124.22 Mn |
| Mar 31, 2025 | -100.92 Mn |
| Dec 31, 2024 | 26,284.00 |
| Sep 30, 2024 | -125.32 Mn |
| Jun 30, 2024 | -199.13 Mn |
| Mar 31, 2024 | -107.79 Mn |
| Dec 31, 2023 | -144,818.00 |
| Sep 30, 2023 | -62.21 Mn |
| Jun 30, 2023 | -199.13 Mn |
| Mar 31, 2023 | -112.10 Mn |
| Dec 31, 2022 | -135.88 Mn |
| Sep 30, 2022 | -84.96 Mn |
| Jun 30, 2022 | -193.23 Mn |
| Mar 31, 2022 | -32.29 Mn |
| Dec 31, 2021 | -88.33 Mn |
| Sep 30, 2021 | -124.75 Mn |
| Jun 30, 2021 | -91.58 Mn |
| Mar 31, 2021 | -90,521.00 |
| Dec 31, 2020 | -57.83 Mn |
| Sep 30, 2020 | -66.55 Mn |
| Jun 30, 2020 | -134.88 Mn |
| Mar 31, 2020 | -44.23 Mn |
| Dec 31, 2019 | -63.94 Mn |
| Sep 30, 2019 | -27.80 Mn |
| Jun 30, 2019 | -28.80 Mn |